Over 1,800 People Registered for the FDA's Psychedelic Drugs Hearing. Here's What They Said.
Yesterday's FDA public hearing — the one set up by this week's NEJM framework piece — drew over 1,800 registrants, hybrid in-person and virtual. FDA's Marta Sokolowska opened by framing it as "a whole of government effort to better understand the opportunities, challenges, and public health considerations" around psychedelic drug treatment. Panelists heard roughly 80 comments across two thematic waves: one on provider training, credentialing, and patient safety; the other on access and standardizing how outcome data gets collected across different providers and settings. None of this is a decision — it's the FDA listening, not ruling — but it's a real, sizable signal of how much public and clinical interest has built around psilocybin and methylone specifically, the two compounds furthest along the agency's own priority-review track.
Read at Behavioral Healthcare Network